The univariable analysis showed that AKI development after TACE is associated with platelet count ≤100 x103/mm2 (odds ratio [OR] 0.24 with 95% confidence interval (CI): 0.07–0.79, p = 0.020), serum AFP ≥100 ng/mL (OR 3.45 with 95% CI: 1.70–6.99, p = 0.001), BCLC stage C (OR 15.91 with 95% CI: 6.39–39.59, p<0.001), use of cisplatin as chemoembolization agents (OR 4.88 with 95% CI: 2.38–10.01, p<0.001), presence of ascites (OR 12.12 with 95% CI: 5.74–25.61, p<0.001) and sessions of TACE ≥2 (OR 2.09 with 95% CI: 1.05–4.15, p = 0.035). The gene discussed is AFP; the disease is acute kidney injury.